Malaria Box results

The Malaria Box compounds were originally tested against the asexual blood stage of P. falciparum by MMV partners and MMV has reconfirmed this activity using a fresh solid sample. The compounds have also been tested for cytotoxicity and all show at least a 10 fold separation between the antimalarial and cytotoxicity results.

As part of MMV’s Open Malaria Box programme, recipients commit to place their data resulting from research on the Malaria Box in the public domain, within 2 years of its generation; either via the ChEMBL database or by publication in a peer-reviewed journal, with an acknowledgement of the source and supplier of the compounds. Publication in an open access journal, in particular, is strongly encouraged.

Published peer-reviewed articles

If your article is missing from the list, please feel free to contact us.

Data deposited in CHEMBL

  • MMV Malaria Box yeast growth screening. (CHEMBL3301546) - St Onge, R.P. Yeast Chemical Genomics Laboratory, Stanford Genome Technology Center, Stanford University.
  • MMV Malaria Box hERG screening. (CHEMBL3301458) - Medicines for Malaria Venture.
  • MMV Malaria Box gametocyte functional viability assay screening. (CHEMBL3301451) - Imperial-Medicines for Malaria Venture Centre of Excellence, Imperial College, London.
  • MMV Malaria Box thermal shift screening. (CHEMBL3301461) - Hui Lab, SGC, University of Toronto, Canada.
  • MMV Malaria Box anti-babesial screening. (CHEMBL3301464) - Igarashi Lab, National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan
  • MMV Malaria Box screening against Plasmodium falciparum Deoxyhypusine hydroxylase. (CHEMBL3301470) - Kaiser Lab, University Hospital Essen, Germany.
  • MMV Malaria Box HIV and cytotoxicity screening. (CHEMBL3301472) - Ketas, T., Moore, J.P., Weill Cornell Medical College, USA.
  • MMV Malaria Box screening against the the NCI60 panel of human tumor cell lines. (CHEMBL3301486) - National Cancer Institute, NIH.
  • MMV Mararia Box screening against P. falciparum asexual stage parasites under hypoxia and bicarbonate modified culture conditions. (CHEMBL3301550) - Poulsen, S-A., Andrews, K.T., Tonissen, K.F., Nawaratna, S., Eskitis Institute for Drug Discovery, Griffith University, Australia.
  • MMV Malaria Box screening in pLDH viability assay against Plasmodium falciparum gametocytes. (CHEMBL3301555) - Taramelli Lab, University of Milan, Italy.
  • MMV Box screening against Plasmodium falciparum protein kinases and aminoacyl tRNA synthetases. (CHEMBL3301562) - Van Voorhis Lab, University of Washington, USA.
  • MMV Malaria Box screening against Toxoplasma gondii and Entamoeba histolytica. (CHEMBL3301448) - Boyom, F.F., Fokou, P.V.T., Tchokouaha, L.R.Y., Spangenberg, T., Mfopa, A.N., Kouipou, R.M.T., Mbouna, C.J., Donkeng Donfack, V.F., Zollo, P.H.A.; University of Yaounde, IMPM Yaounde and MMV.
  • Cytotoxicity against human fibroblasts (MRC-5) cells. (CHEMBL2095143) – Louis Maes, An Matheeussen et al (Universiteit Antwerpen) & Drugs for Neglected Diseases Initiative (DNDi)
  • Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro). (CHEMBL2028075) - Louis Maes, An Matheeussen et al (Universiteit Antwerpen) & Drugs for Neglected Diseases Initiative (DNDi)
  • Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro). (CHEMBL2028073) – Louis Maes, An Matheeussen et al (Universiteit Antwerpen) & Drugs for Neglected Diseases Initiative (DNDi)
  • Inhibition of Leishmania infantum (MHOM/MA/BE/67 in vitro). (CHEMBL2028076) – Louis Maes, An Matheeussen et al (Universiteit Antwerpen) & Drugs for Neglected Diseases Initiative (DNDi)
  • Malaria Box Tuberculosis Screening Data. Single point screen at 25 µM against Mtb nonreplicating (CHEMBL2094261) and replicating (CHEMBL2094262). CRC and MIC90 against Mtb nonreplicating (CHEMBL2094263) and replicating (CHEMBL2094264), Citation: Gold B, Warrier T, Somersan S, Lopez-Quezada L, Roberts J, Little D, Nathan C. (2013)
  • Toxicity at 2.5 µM to newly transformed Schistosoma mansoni somules after 24 h (CHEMBL2363023), 48 h (CHEMBL2363024) and 72 h (CHEMBL2363025) on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541) - Conor Caffrey and Brian Suzuki; Center for Discovery and Innovation in Parasitic Diseases, Dept. of Pathology, University of California San Francisco
  • Toxicity at 5 µM to Schistosoma mansoni adult males after 24 h (CHEMBL2363026), 48 h (CHEMBL2363027) and 72 h (CHEMBL2363028) on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541) - Conor Caffrey and Brian Suzuki; Center for Discovery and Innovation in Parasitic Diseases, Dept. of Pathology, University of California San Francisco
  • Percent change (relative to DMSO controls) at 5 µM of movement of 4-5 Schistosoma mansoni adult males after 24 h (CHEMBL2363029), 48 h (CHEMBL2363030) and 72 h (CHEMBL2363031) as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493). Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'. In these cases the 'toxicity score' should be prioritized. Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested - Conor Caffrey and Brian Suzuki; Center for Discovery and Innovation in Parasitic Diseases, Dept. of Pathology, University of California San Francisco
  • Raw screening data for the screening of the P. falciparum W2 strain in a 72 hr growth at 5 µM using the assay monitored by flow cytometry both in the presence and absence of supplemental IPP. The DeRisi lab,  UCSF

Assistance for depositing data in ChEMBL can be found on the ChEMBL website or by contacting Prudence Mutowo (prudence [at] ebi.ac.uk).